BidaskClub upgraded shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) from a sell rating to a hold rating in a report published on Tuesday, BidAskClub reports.

Several other equities research analysts have also recently weighed in on DRNA. B. Riley set a $24.00 target price on shares of Dicerna Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, July 3rd. Zacks Investment Research upgraded shares of Dicerna Pharmaceuticals from a sell rating to a hold rating in a research note on Monday, July 22nd. ValuEngine upgraded shares of Dicerna Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, June 11th. SunTrust Banks reduced their target price on shares of Dicerna Pharmaceuticals to $20.00 and set a buy rating for the company in a research note on Thursday, May 16th. Finally, HC Wainwright reiterated a buy rating and issued a $22.00 target price on shares of Dicerna Pharmaceuticals in a research note on Monday, July 15th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Dicerna Pharmaceuticals has a consensus rating of Buy and a consensus target price of $21.57.

Shares of NASDAQ:DRNA opened at $14.47 on Tuesday. The firm has a market capitalization of $928.52 million, a P/E ratio of -12.06 and a beta of 2.16. The company has a 50-day simple moving average of $14.51. Dicerna Pharmaceuticals has a 52-week low of $9.31 and a 52-week high of $17.98. The company has a current ratio of 5.00, a quick ratio of 5.00 and a debt-to-equity ratio of 0.01.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.03). Dicerna Pharmaceuticals had a negative net margin of 737.93% and a negative return on equity of 48.98%. The company had revenue of $5.68 million during the quarter, compared to the consensus estimate of $10.95 million. Research analysts predict that Dicerna Pharmaceuticals will post -1.35 EPS for the current fiscal year.

In other Dicerna Pharmaceuticals news, Director Bain Capital Life Sciences Inv sold 1,600,000 shares of the firm’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $12.50, for a total transaction of $20,000,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 21.28% of the stock is owned by company insiders.

Several large investors have recently bought and sold shares of the company. Artal Group S.A. grew its holdings in Dicerna Pharmaceuticals by 2.1% during the 2nd quarter. Artal Group S.A. now owns 1,000,000 shares of the biopharmaceutical company’s stock worth $15,750,000 after acquiring an additional 20,725 shares during the period. Northern Trust Corp grew its holdings in Dicerna Pharmaceuticals by 3.7% during the 2nd quarter. Northern Trust Corp now owns 683,682 shares of the biopharmaceutical company’s stock worth $10,768,000 after acquiring an additional 24,348 shares during the period. Geode Capital Management LLC grew its holdings in Dicerna Pharmaceuticals by 24.4% during the 4th quarter. Geode Capital Management LLC now owns 554,957 shares of the biopharmaceutical company’s stock worth $5,932,000 after acquiring an additional 109,012 shares during the period. Deutsche Bank AG grew its holdings in Dicerna Pharmaceuticals by 43.2% during the 4th quarter. Deutsche Bank AG now owns 505,306 shares of the biopharmaceutical company’s stock worth $5,400,000 after acquiring an additional 152,331 shares during the period. Finally, Candriam Luxembourg S.C.A. grew its holdings in Dicerna Pharmaceuticals by 7.2% during the 2nd quarter. Candriam Luxembourg S.C.A. now owns 479,800 shares of the biopharmaceutical company’s stock worth $9,860,000 after acquiring an additional 32,300 shares during the period. Institutional investors own 85.08% of the company’s stock.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

See Also: What is the significance of a dead cat bounce?

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.